Share this article
Share this article
LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ Heska Corporation (NASDAQ: HSKA; Heska or Company ), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company s Board of Directors, effective January 11, 2021.
Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion of the business, including the acquisition of a significant part of the Fort Dodge Animal Health product portfolio as well as the acquisition and integration of the Sanofi/Merial animal health units. Dr. Hasenmaier received his Doctor of Veterinary Medicine de
LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ Heska Corporation , a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the.
Animal Vaccines Market Growth Analysis, Opportunities and Forecast To 2025 marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Jardiance® associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Share Article
Highmark and Boehringer Ingelheim announced positive results from their outcomes-based agreement, which showed that adults with type 2 diabetes and known cardiovascular disease who took Jardiance® (empagliflozin) had a lower annual total cost of care compared with those prescribed other branded or generic anti-hyperglycemic medications. Patients on Jardiance demonstrated a reduction in medical costs of over 30%. Factoring in both medical and pharmacy costs, the overall total cost of care reduction was more than 20% for patients on Jardiance.